{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:17:04Z","timestamp":1794629824554,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100024506","name":"Faculty of Medical Sciences, Tarbiat Modares University","doi-asserted-by":"publisher","award":["MED-98508949"],"award-info":[{"award-number":["MED-98508949"]}],"id":[{"id":"10.13039\/501100024506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-026-07630-y","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:35:59Z","timestamp":1770150959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ranolazine attenuates diabetic cardiomyopathy in rats by suppressing AGE-RAGE axis and oxidative stress"],"prefix":"10.1186","volume":"19","author":[{"given":"Fatemeh","family":"Ebrahimpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Zahra","family":"Bathaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6807","authenticated-orcid":false,"given":"Hamid","family":"Yaghooti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"4","key":"7630_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","volume":"10","author":"MZ Banday","year":"2020","unstructured":"Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. 2020;10(4):174\u201388. https:\/\/doi.org\/10.4103\/ajm.ajm_53_20.","journal-title":"Avicenna J Med"},{"issue":"3","key":"7630_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/jpm13030406","volume":"13","author":"CY Chou","year":"2023","unstructured":"Chou CY, Hsu DY, Chou CH. Predicting the onset of diabetes with machine learning methods. J Pers Med. 2023;13(3):406. https:\/\/doi.org\/10.3390\/jpm13030406.","journal-title":"J Pers Med"},{"issue":"4","key":"7630_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14341\/probl13414","volume":"70","author":"AD Erlikh","year":"2024","unstructured":"Erlikh AD, Zilov AV, Shchekochikhin DY, Shornikov SB, Bublik EV, Vinogradskaya OI, et al. [Summary of the 2023 European society of cardiology clinical guidelines on the management of cardiovascular disease in patients with diabetes mellitus]. Probl Endokrinol. 2024;70(4):94\u2013102.","journal-title":"Probl Endokrinol"},{"issue":"10","key":"7630_CR4","doi-asserted-by":"publisher","first-page":"108848","DOI":"10.1016\/j.jdiacomp.2024.108848","volume":"38","author":"XF Geng","year":"2024","unstructured":"Geng XF, Shang WY, Qi ZW, Zhang C, Li WX, Yan ZP, et al. The mechanism and promising therapeutic strategy of diabetic cardiomyopathy dysfunctions: focus on pyroptosis. J Diabetes Complications. 2024;38(10):108848. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108848.","journal-title":"J Diabetes Complications"},{"key":"7630_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cca.2021.03.001","volume":"517","author":"H Wan","year":"2021","unstructured":"Wan H, Zhao S, Zeng Q, Tan Y, Zhang C, Liu L, et al. CircRNAs in diabetic cardiomyopathy. Clin Chim Acta. 2021;517:127\u201332. https:\/\/doi.org\/10.1016\/j.cca.2021.03.001.","journal-title":"Clin Chim Acta"},{"key":"7630_CR6","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.bone.2023.116884","volume":"176","author":"R Pal","year":"2023","unstructured":"Pal R, Bhadada SK. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review. Bone. 2023;176:116884. https:\/\/doi.org\/10.1016\/j.bone.2023.116884.","journal-title":"Bone"},{"issue":"1","key":"7630_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10741-013-9374-y","volume":"19","author":"VL Bodiga","year":"2014","unstructured":"Bodiga VL, Eda SR, Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2014;19(1):49\u201363. https:\/\/doi.org\/10.1007\/s10741-013-9374-y.","journal-title":"Heart Fail Rev"},{"key":"7630_CR8","doi-asserted-by":"publisher","first-page":"695792","DOI":"10.3389\/fmed.2021.695792","volume":"8","author":"T Salvatore","year":"2021","unstructured":"Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, et al. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. Front Med (Lausanne). 2021;8:695792. https:\/\/doi.org\/10.3389\/fmed.2021.695792.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"7630_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","volume":"97","author":"G Hasenfuss","year":"2008","unstructured":"Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug Ranolazine. Clin Res Cardiol. 2008;97(4):222\u20136. https:\/\/doi.org\/10.1007\/s00392-007-0612-y.","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"7630_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2337\/dc14-2629","volume":"38","author":"RH Eckel","year":"2015","unstructured":"Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, et al. Effect of Ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015;38(7):1189\u201396. https:\/\/doi.org\/10.2337\/dc14-2629.","journal-title":"Diabetes Care"},{"issue":"1","key":"7630_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of Ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehi495.","journal-title":"Eur Heart J"},{"issue":"1","key":"7630_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/jpet.110.176396","volume":"337","author":"Y Ning","year":"2011","unstructured":"Ning Y, Zhen W, Fu Z, Jiang J, Liu D, Belardinelli L, et al. Ranolazine increases \u03b2-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50\u20138. https:\/\/doi.org\/10.1124\/jpet.110.176396.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"7630_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1060028016631757","volume":"50","author":"L Greiner","year":"2016","unstructured":"Greiner L, Hurren K, Brenner M. Ranolazine and its effects on hemoglobin A1C. Ann Pharmacother. 2016;50(5):410\u20135. https:\/\/doi.org\/10.1177\/1060028016631757.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"7630_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21608\/muj.2020.25106.1007","volume":"1","author":"SE Elkholy","year":"2020","unstructured":"Elkholy SE. The possible antidiabetic effects of Ranolazine versus Gliclazide in HFD\/STZ-induced type 2 diabetes in male albino rats. Med Updates. 2020;1(1):9\u201328.","journal-title":"Med Updates"},{"key":"7630_CR15","doi-asserted-by":"publisher","first-page":"598638","DOI":"10.1155\/2012\/598638","volume":"2012","author":"PRM Perez Gutierrez","year":"2012","unstructured":"Perez Gutierrez PRM Inhibition of advanced glycation end-product formation by Origanum majorana L. In vitro and in Streptozotocin-Induced diabetic rats. Evid Based Complement Alternat Med. 2012;2012:598638. https:\/\/doi.org\/10.1155\/2012\/598638.","journal-title":"Evid Based Complement Alternat Med"},{"key":"7630_CR16","doi-asserted-by":"publisher","first-page":"4952447","DOI":"10.1155\/2021\/4952447","volume":"2021","author":"A Nusca","year":"2021","unstructured":"Nusca A, Bernardini F, Mangiacapra F, Maddaloni E, Melfi R, Ricottini E, et al. Ranolazine improves glycemic variability and endothelial function in patients with diabetes and chronic coronary syndromes: results from an experimental study. J Diabetes Res. 2021;2021:4952447. https:\/\/doi.org\/10.1155\/2021\/4952447","journal-title":"J Diabetes Res"},{"issue":"6","key":"7630_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10557-019-06917-6","volume":"33","author":"D Lisi","year":"2019","unstructured":"Lisi D, Andrews E, Parry C, Hill C, Ombengi D, Ling H. The effect of Ranolazine on glycemic control: a narrative review to define the target population. Cardiovasc Drugs Ther. 2019;33(6):755\u201361. https:\/\/doi.org\/10.1007\/s10557-019-06917-6.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7630_CR18","doi-asserted-by":"publisher","first-page":"e000706","DOI":"10.1136\/openhrt-2017-000706","volume":"5","author":"IH Teoh","year":"2018","unstructured":"Teoh IH, Banerjee M. Effect of Ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials. Open Heart. 2018;5(2):e000706. https:\/\/doi.org\/10.1136\/openhrt-2017-000706.","journal-title":"Open Heart"},{"issue":"2","key":"7630_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10840-021-01016-9","volume":"63","author":"H Mashayekhi-Sardoo","year":"2022","unstructured":"Mashayekhi-Sardoo H, Mohammadpour AH, Mehri S, Kamali H, Sahebkar A, Imenshahidi M. Diabetes mellitus aggravates ranolazine-induced ECG changes in rats. J Interv Card Electrophysiol. 2022;63(2):379\u201388. https:\/\/doi.org\/10.1007\/s10840-021-01016-9.","journal-title":"J Interv Card Electrophysiol"},{"key":"7630_CR20","doi-asserted-by":"publisher","first-page":"3085756","DOI":"10.1155\/2019\/3085756","volume":"2019","author":"NT Moldogazieva","year":"2019","unstructured":"Moldogazieva NT, Mokhosoev IM, Mel\u2019nikova TI, Porozov YB, Terentiev AA Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age-related diseases. Oxid Med Cell Longev. 2019;2019:3085756. https:\/\/doi.org\/10.1155\/2019\/3085756.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"7630_CR21","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.26355\/eurrev_202304_31927","volume":"27","author":"Z Do\u011fan","year":"2023","unstructured":"Do\u011fan Z, Durmus S, Ergun D, Geli\u015fgen R, Uzun H. Ranolazine exhibits anti-inflammatory and antioxidant activities in H9c2 cardiomyocytes. Eur Rev Med Pharmacol Sci. 2023;27(7):2953\u201363. https:\/\/doi.org\/10.26355\/eurrev_202304_31927.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"7630_CR22","doi-asserted-by":"publisher","first-page":"931473","DOI":"10.3389\/fimmu.2022.931473","volume":"13","author":"H Dong","year":"2022","unstructured":"Dong H, Zhang Y, Huang Y, Deng H. Pathophysiology of RAGE in inflammatory diseases. Front Immunol. 2022;13:931473. https:\/\/doi.org\/10.3389\/fimmu.2022.931473.","journal-title":"Front Immunol"},{"issue":"1","key":"7630_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40360-025-00945-9","volume":"26","author":"M Mohyadini","year":"2025","unstructured":"Mohyadini M, Fahimi A, Bathaie SZ, Yaghooti H. Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing Endoplasmic reticulum stress and inflammation in type 2 diabetic rat model. BMC Pharmacol Toxicol. 2025;26(1):111. https:\/\/doi.org\/10.1186\/s40360-025-00945-9.","journal-title":"BMC Pharmacol Toxicol"},{"key":"7630_CR24","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.phrs.2024.107282","volume":"206","author":"M Zhou","year":"2024","unstructured":"Zhou M, Zhang Y, Shi L, Li L, Zhang D, Gong Z, et al. Activation and modulation of the AGEs-RAGE axis: implications for inflammatory pathologies and therapeutic interventions - A review. Pharmacol Res. 2024;206:107282. https:\/\/doi.org\/10.1016\/j.phrs.2024.107282.","journal-title":"Pharmacol Res"},{"issue":"2","key":"7630_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/011871529X356362250324080014","volume":"25","author":"KN Tentolouris","year":"2025","unstructured":"Tentolouris KN, Anastasiou IA, Mourouzis I, Pantos C, Tentolouris N. Ranolazine: an established anti-anginal drug with emerging antidiabetic potential supported by preclinical and clinical evidence. Cardiovasc Hematol Disord Drug Targets. 2025;25(2):87\u201397. https:\/\/doi.org\/10.2174\/011871529X356362250324080014.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"7630_CR26","doi-asserted-by":"publisher","first-page":"10604","DOI":"10.3389\/ebm.2025.10604","volume":"250","author":"D Singh","year":"2025","unstructured":"Singh D, Oladimeji-Salami JA, Akindele AJ. Unraveling the Pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight. Exp Biol Med. 2025;250:10604. https:\/\/doi.org\/10.3389\/ebm.2025.10604.","journal-title":"Exp Biol Med"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07630-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:28:11Z","timestamp":1772620091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07630-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7630"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07630-y","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Animal Ethics Committee Guidelines and was approved by the Ethics Committee of Tarbiat Modares University (IR.MODARES.AEC.1402.042).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}